Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48 + sintilimab + SOX neoadjuvant therapy in HER2-expressing bulky Borrmann III/IV gastric/GEJ adenocarcinoma
ChiCTR2500106363Phase 2Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin, sintilimab, oxaliplatin and tegafur in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Sichuan Cancer Hospital. Primary endpoints: Major pathological response (MPR) and Adverse events. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
disitamab vedotinsintilimaboxaliplatintegafur
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500106363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106363.